Kamada reports positive results in cystic fibrosis study
Nasal AAT achieved significant reduction in inflammation in the lungs.
Gali Weinreb15 Oct 08 15:36
Kamada Ltd. (TASE: KMDA) reports positive results of its Phase II clinical trial of its Alpha-1 Antitrypsin (AAT) protein for the treatment of cystic fibrosis. The company said that AAT achieved significant reduction in inflammation in the lungs, compared with the placebo. Lung inflammation is the main symptom of the disease and the main cause of patients' deterioration.
On the basis of the trial results, Kamada will now be able to begin Phase III clinical trials with the US Food and Drug Administration (FDA). The Phase II trial was conducted with the European Medicines Agency (EMEA).